Takeshi Ohara
Japan
Research Article
Empagliflozin Ameliorating Effect of on Plasma Triglyceride: An Association with Endothelial Function Recovery in Diabetic Patients with Coronary Artery Disease
Author(s): Takahiro Sawada, Kenzo Uzu, Naoko Hashimoto, Tetsuari Onishi, Tomohumi Takaya, Tomohumi Takaya, Akira Shimane, Yasuyo Taniguchi, Yoshinori Yasaka, Takeshi Ohara and Hiroya KawaiTakahiro Sawada, Kenzo Uzu, Naoko Hashimoto, Tetsuari Onishi, Tomohumi Takaya, Tomohumi Takaya, Akira Shimane, Yasuyo Taniguchi, Yoshinori Yasaka, Takeshi Ohara and Hiroya Kawai
Introduction: The mechanisms behind the cardiovascular benefits of Sodium-Glucose Co-Transporter 2 (SGLT2) inhibitors have not been fully clarified. We aimed to identify potential mechanisms underlying the favorable effects of SGLT2 inhibitors on cardiovascular events.
Methods: The 50 diabetic patients with established Coronary Artery Disease (CAD) included in this study analysis were administered 10 mg/day of empagliflozin. Cookie meal testing (carbohydrates: 75 g, fat: 28.5 g), endothelial function testing using Flow-Mediated Dilatation (FMD), and body composition evaluation were performed before and after 6 months treatments. Evaluation of changes in % FMD between treatment periods, and its association with metabolic biomarkers were evaluated.
.. View More»
